Given the complexity of the OCCC TME, therapeutic strategies that combine ICIs with agents targeting key molecules implicated in tumor aggressiveness such as VEGF, HIF-1α, IL-6, IL-10, PI3K, and HDAC6 show considerable promise (Figure 3). This evidence concerns the gene HDAC6 and neoplasm.